Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VIVS vs ASMB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ASMB Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–3 Matrix Metrics)

ASMB Overall Winner 6-Pillar Tally: VIVS 1 – 5 ASMB Matrix Metrics: VIVS 3 – 6 ASMB

As of Nov 19, 2026, Assembly Biosciences, Inc (ASMB) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas ASMB carries 31.0/100 (SELL) at $22.50 (N/M Forward P/E, -31.8% operating margin).

  • Composite vs. Pillar Nuance: While VIVS currently prints a higher short-term Unified Composite Score (39.0/100 SELL vs. ASMB 31.0/100 SELL), ASMB captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-31.8% vs. -10117.0% operating margin) and revenue trajectory (-72.6% vs. -51.4% YoY).
  • Defensive Composite Rating Caution: Although ASMB compares more favorably head-to-head, both VIVS (39.0/100 SELL) and ASMB (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ASMB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 55.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIVS vs ASMB
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 5.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18
ASMB NASDAQ Head-to-Head Winner
Assembly Biosciences, Inc
Pharmaceutical Preparations
$22.50
+0.49% 1D
Market Cap $464.6M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.99β · 57% Vol
Unified Composite Score
31.0 / 100 SELL
Tech 3.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 56
RSI-14: 55.7 · SMA20: $20.83 · SMA50: $22.32

6-Pillar Scorecard Institutional Category Breakdown (VIVS 1 – 5 ASMB)

Columns: Metric · VIVS · ASMB
1. Valuation Multiples ASMB
Forward P/E N/M N/M
Trailing P/E N/M 30.2x
PEG Ratio N/M N/M
EV / Revenue 9.6x 6.9x
2. Growth & Scale ASMB
Revenue Growth (YoY) -51.4% -72.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $112,000 $67M
Market Cap $2.4M $464.6M
3. Profitability & Quality ASMB
Gross Margin N/A -0.4%
Operating Margin -10117.0% -31.8%
Net Profit Margin 0.0% -16.6%
Return on Equity (ROE) -343.1% -4.6%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$11M EBITDA -$21M EBITDA
Cash Flow Margin N/A -31.7% EBITDA Mgn
Net Cash / Leverage $1.4M Net Cash $14.67 Book/Sh · -4.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ASMB
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) 109.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ASMB
OpEx & R&D Intensity N/A 31.4% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIVS (3) vs ASMB (6)
Institutional Metric VIVS ASMB Criterion Row Edge
Market Capitalization
Scale
$2.4M $464.6M Larger Scale ASMB
Trailing P/E Ratio
Valuation
N/M 30.2x Lower Multiple ASMB
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-51.4% -72.6% Higher Growth VIVS
Operating Margin (TTM)
Profitability
-10117.0% -31.8% Higher Margin ASMB
Net Profit Margin
Profitability
0.0% -16.6% Higher Margin VIVS
Return on Equity (ROE)
Capital Efficiency
-343.1% -4.6% Higher ROE ASMB
52-Week Range Position
Momentum
5% ($0–$3) 16% ($19–$40) Stronger Trend ASMB
Beta / 30D Volatility
Risk Regime
0.83β · 480% Vol 0.99β · 57% Vol Lower Realized Risk ASMB
Unified Institutional Score
Composite Signal
39.0 / 100 (SELL) 31.0 / 100 (SELL) Higher Composite VIVS
Trailing 12M Revenue (USD)
Operating Scale
$112,000 $67M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -0.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev N/M PEG · 6.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.4M Net Cash) -$21M EBITDA ($14.67 Book/Sh · -4.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +54.72 pp
VIVS: +64.69% · ASMB: +9.97%
3M Horizon VIVS +36.47 pp
VIVS: +1.92% · ASMB: -34.55%
6M Horizon ASMB +63.16 pp
VIVS: -78.25% · ASMB: -15.09%
1Y Horizon ASMB +49.68 pp
VIVS: -86.99% · ASMB: -37.31%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIVS vs ASMB. Trailing 12-month operating profitability (VIVS -10117.0% vs ASMB -31.8%) and valuation multiples (VIVS N/M vs ASMB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VIVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$112,000
Gross MarginN/A
Op. Margin-10117.0%
ROE / Fwd P/E-343.1% · N/M
ASMB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$67M
Gross Margin-0.4%
Op. Margin-31.8%
ROE / Fwd P/E-4.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ASMB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 109.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ASMB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ASMB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $464.6M market capitalization and -31.8% operating margin.
OpEx & R&D Reinvestment 31.4% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ VIVS vs ASMB Key Questions & Quantitative Answers

As of Nov 19, 2026, Assembly Biosciences, Inc (ASMB) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas ASMB carries 31.0/100 (SELL) at $22.50 (N/M Forward P/E, -31.8% operating margin). Composite vs. Pillar Nuance: While VIVS currently prints a higher short-term Unified Composite Score (39.0/100 SELL vs. ASMB 31.0/100 SELL), ASMB captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-31.8% vs. -10117.0% operating margin) and revenue trajectory (-72.6% vs. -51.4% YoY). Defensive Composite Rating Caution: Although ASMB compares more favorably head-to-head, both VIVS (39.0/100 SELL) and ASMB (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ASMB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 55.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ASMB leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with ASMB at -72.6% YoY revenue growth and +0.0% YoY earnings growth on $67M TTM revenue (-0.4% gross margin, -31.8% operating margin). On trailing 12-month operating scale, VIVS generates $112,000 in USD-normalized revenue versus $67M for ASMB. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus 31.4% of Rev ($21M) (0 disclosures) for ASMB.

ASMB screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas ASMB trades at N/M Forward P/E, 30.2x Trailing P/E, N/M PEG, and 6.9x EV/Revenue (-31.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus ASMB (-4.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, ASMB carries 109.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.99β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.